

Disclosure of Payments

Eisai BV fully supports the transparency requirements in the European Federation of Pharmaceutical Industries and Associations' (EFPIA) Disclosure Code, local codes of practice and local laws, and is committed to making public the details of all transfers of value made to healthcare professionals and healthcare organisations.

Eisai BV adheres to the Code of Conduct Pharmaceutical Advertising (the “CGR Code”) of the Foundation for the Code for Pharmaceutical Advertising (the “CGR”) to document and publicly disclose transfers of value made to Healthcare Professionals (HCP’s) and Healthcare Organizations (HCO’s). The Code of Conduct states that financial relationships between license holders and healthcare providers or patient organizations must be reported to the Healthcare Transparency Register if the relationship exceeds the lower limit of €500 per calendar year.

This disclosure is made in the Transparency Register of the STZ (Stichting Transparantie Zorg), which is accessible using the links below:

<https://www.transparantieregister.nl/home> (Dutch version)

<https://www.transparantieregister.nl/home?lang=en-us> (English version)

Financial ties that are registered in the Transparantieregister Zorg:

- Consulting Services: Lectures or presentations, or advice for which a remuneration is paid based on hourly fee and time. Expenses such as travel expenses are listed separately.
- Hospitality: HCP’s may receive a contribution for registration fees for participating in a (clinical) meeting, as well as travel and accommodation expenses.
- Sponsoring: Sponsoring a project carried out by a healthcare organization or patient organization, for instance in exchange for mentioning the company’s name. For sponsorships, there are two varieties: sponsorship project and sponsorship meeting. An example of sponsorship is the sponsoring of a scientific congress organized by a scientific association. For individual healthcare professionals, companies can only reimburse printing expenses for a PhD thesis, according to the codes of conduct. This is characterized as ‘sponsoring project’ in the name of the individual healthcare professional.

Financial ties that are not registered in the Transparantieregister Zorg:

- Financial ties that do not exceed €500 in a calendar year (per HCP or HCO)
- Research and Development, as this is regulated by other legal frameworks and oversight is conducted by other committees.

Research and Development

Costs for Research and Development are not included in this transparency register. In order to make research and development costs as transparent as possible, EFPIA (European Federation of Pharmaceutical Industries and Associations) asked all member pharmaceutical companies to publish their research and development costs on their own websites ([click here](#) for the EFPIA

Disclosure Code). R&D expenses consist of expenses on non-clinical studies, clinical trials, prospective non-intervention studies and include research-related costs. The costs are made public annually on an aggregated basis and each reporting period covers a full calendar year.

The amount paid in the Netherlands in 2023 was € 46,000

The amount paid in the Netherlands in 2024 was € 164,047

The amount paid in the Netherlands in 2025 was € 41,984